These drugs were sunitinib (a receptor tyrosine kinase inhibitor), pazopanib (used to treat a subtype of BCR-ABL-positive cancer albeit with a specific type of mutation), and AMG-706 (an angiokinase inhibitor)). The gene discussed is ABL1; the disease is cancer.